The emergence of EGFR degraders not only provides new therapeutic approaches for solving EGFR inhibitor resistance but, more importantly, their potential as monotherapy in first‐line settings may avoid secondary EGFR mutations commonly seen with currently approved EGFR inhibitors, potentially providing more durable treatment benefits for EGFR‐mutated NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.